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Abstract
Objectives:  Ximelagatran is a novel oral direct thrombin inhibitor. It has favorable
pharmacodynamic properties, with a broad therapeutic range without the need for anticoagulation
monitoring. We aimed to discover whether ximelagatran offers a genuine future replacement to
warfarin for patients in persistent atrial fibrillation (AF).
Materials and methods: We provide an evidence-based review of the relative merits and
disadvantages of warfarin and aspirin. We subsequently present an overview of the evidence for
the utility of ximelagatran in the treatment of AF.
Results: Adjusted dose warfarin is recommended over aspirin for patients in AF at high risk of
future stroke. Some of this benefit is partially offset by the higher bleeding risks associated with
warfarin therapy. The SPORTIF III and V studies have shown that ximelagatran is not inferior to
warfarin in the prevention of all strokes in patients with AF (both persistent and paroxysmal). This
benefit was partially offset by the finding of a significant elevation of liver transaminases (>3 ×
normal) in 6% of patients.
Conclusions: Current data would suggest that ximelagatran might represent a future alternative
to warfarin. The lack of need for anticoagulant monitoring has been partially offset by a need for
regular monitoring of liver function. Further data from randomized clinical trials is clearly needed.
Introduction
Atrial Fibrillation (AF) is the most common sustained
tachyarrhythmia encountered in clinical practice [1], with
an incidence that doubles with every decade after 55 years
of age [2]. With an aging population and improved sur-
vival of patients with cardiac disease, its prevalence con-
tinues to rise and currently affects as many as 5% of
persons ≥ 65 years old [3]. Consequently, AF has become
a "new epidemic" of cardiovascular disease in Western
society [4].
AF is not a benign problem. It is associated with a dou-
bling of overall morbidity and mortality from cardiovas-
cular disease [5] and it is the most common cause of
embolic stroke [6]. Patients with non-rheumatic AF
(NRAF) have a 5.6-fold greater risk for embolism, and
those with AF of rheumatic valvular origin have a 17.6-
fold greater risk, as compared to healthy control individu-
als [7]. This equates to an increased incidence of stroke
approximating 5% per year for primary events and 12%
per year for recurrent events [8,9].
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Oral anticoagulant therapy has been shown to reduce the
thromboembolic risk of AF. At 60 years post introduction,
warfarin still remains the mainstay of oral anticoagulant
treatment. Despite its demonstrated superior efficacy over
aspirin for the prevention of stroke in AF, warfarin treat-
ment is complicated by a magnitude of potential prob-
lems, which limit its use, with patients walking a tight
rope between bleeding and clotting [2,9]. In this article we
present an evidence-based overview of current knowledge
about oral anticoagulation in atrial fibrillation.
We initially review the relative merits and disadvantages
of warfarin and aspirin. This is followed by an up-to-date
assessment of the new oral anticoagulant ximelagatran,
which offers the potential to be a genuine and long-
awaited replacement for warfarin therapy in patients with
atrial fibrillation.
Evidence for warfarin and aspirin
Five randomized controlled clinical trials of warfarin (see
Table 1 and Additional file: 1) versus control or placebo
have demonstrated the effectiveness of antithrombotic
therapy for the prevention of stroke in patients with NRAF
[10-14]. Meta-analysis of these five primary prevention
trials concluded that the relative risk of stroke was reduced
by 68% (from 4.5% per year to 1.6% per year, 95% CI 50–
79% p < 0.001), whereas the risk of major bleeding
increased (from 1.0% to 1.3%) [15]. The European Atrial
Fibrillation Trial compared warfarin, aspirin and placebo
in patients with NRAF who had experienced a transient
ischemic attack or stroke within the previous three
months [16]. The risk of recurrence was 12% among pla-
cebo patients, dramatically higher than the 4.5% annual
risk in the overall population of patients with NRAF. The
relative risk reduction with warfarin was 66% (p < 0.001),
virtually identical to that calculated in the five major ran-
domized controlled trials, but the absolute reduction in
strokes was much greater (80 per year per 1000 versus 31
per year per 1000) because of the high baseline stroke rate
in this population [16].
The reduction in the risk of stroke afforded by aspirin,
although less pronounced than that for adjusted-dose
warfarin, is still significant. Meta-analysis of the six rand-
omized trials of aspirin versus placebo (see Table 2 and
Additional file: 2) has shown that aspirin significantly
reduces the risk of stroke by 22% (95% CI 2%–38%), with
no significant increase in the risk of major hemorrhage
[10,11,16-21]. Aspirin leads to an absolute stroke risk
reduction of 1.5% a year for primary prevention and 2.5%
per year for secondary prevention (numbers needed to
treat of 66 and 40, respectively).
Meta-analysis of five randomized trials comparing aspirin
with warfarin for the primary prevention of stroke in
NRAF (see Table 3 and Additional file: 3) showed that
warfarin reduces the risk of stroke compared with aspirin
by 36% (95% CI: 14%–52%) [10,16,21-24]. Low-inten-
sity warfarin alone or in combination with aspirin is sig-
nificantly less effective than adjusted-dose warfarin for
this indication [25].
Current practice guidelines and evidence from further tri-
als provide recommendations for adjusted-dose warfarin
(international normalized ratio [INR], 2.0–3.0) for
patients at high risk of future stroke [26-28]. Several pub-
lished guidelines describe for physicians which AF patient
groups are at high risk of stroke and which groups would
gain relative benefit from warfarin therapy. The current
recommendations of the American College of Chest Phy-
sicians are summarized. (see Table 4 and Additional file:
4) [8,29].
Problems with warfarin therapy
Despite the efficacy of warfarin therapy, there are several
inherent problems related to its use. Warfarin exerts its
pharmacokinetic effects by reducing the synthesis of vita-
min K-dependent procoagulant factors II, VII, IX and X.
Warfarin's dose response is influenced by numerous drug
interactions (it is metabolized by the P450 enzyme com-
plex), hepatic dysfunction, changes in the gut flora, and
patient compliance and alcohol intake [30]. Warfarin has
a very narrow therapeutic range, with marked variability
in its dosage response that necessitates frequent venipunc-
ture to maintain appropriate dosage [31]. Clinical trials
have demonstrated that ischemic stroke is far more likely
with an INR < 2.0, whereas an INR > 4.0 increases the risk
of intracranial hemorrhage [32-34].
These concerns over warfarin use have resulted in consid-
erable under-treatment of a large proportion of AF
patients at risk, the very population that would most ben-
efit from anticoagulant therapy [35-37]. Failure to pre-
scribe anticoagulant agents to these patients is often due
to physicians' perceiving the risk of major bleeding as
unacceptably high because of the presence of such clinical
risk factors as hypertension, falls, a history of gastrointes-
tinal tract bleeding, worries about drug interactions and
lack of assurance about compliance [38-43]. Unfortu-
nately, attempts to reduce the potential risk of bleeding
using a low- and fixed-dose of warfarin have been unsuc-
cessful, being associated with a four-fold increased risk in
stroke [43-45].
Ximelagatran
Ximelagatran (Astra Zeneca) is a novel oral direct
thrombin inhibitor (oral DTI) that is rapidly converted to
melagatran, its active form, following absorption [46].
Melagatran has been shown to be a potent, rapidly bind-
ing competitive inhibitor of human alpha-thrombin thatCurrent Controlled Trials in Cardiovascular Medicine 2004, 5 http://cvm.controlled-trials.com/content/5/1/3
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inhibits both thrombin activity and thrombin generation
(see Figure 1) [47]. Melagatran has a broad therapeutic
interval that enables it to be administered safely across a
wide range of doses with no increased risk of bleeding.
Although melagatran has all the pharmacodynamic prop-
erties required of a new antithrombotic agent, it unfortu-
nately exhibits low oral bioavailability, which is further
reduced by the concomitant intake of food. This limita-
tion precluded its development as an oral agent, but it did
propel the development of its precursor, ximelagatran,
which is 170 times more lipophilic than melagatran and
remains uncharged at intestinal pH. Ximelagatran is there-
fore much better than melagatran at penetrating the gas-
trointestinal barrier and, as a consequence, has sufficient
bioavailability (20%) for oral administration with low
between-subject variation [47,48].
The absorption and bioconversion of ximelagatran to
melagatran is rapid. The maximum plasma concentration
of melagatran is achieved 2–3 hours after oral ximelagat-
ran administration, with a mean half-life elimination of
three hours. Its pharmacokinetic profile is predictable and
stable over time [49,50], and is unaffected by patient body
weight, age, sex, or ethnic origin [50-52]. With a metabo-
lism that is independent of the hepatic P450 system,
ximelagatran exhibits low potential for drug interactions
and has no known food interactions [49,50,53,54], mak-
ing coagulation monitoring and dose adjustments unnec-
essary [50-52]. Recent data, however, suggest that in
patients with severe renal impairment, a reduction in dose
and/or an increase in the administration interval would
be appropriate [55]. At present there is no reversal agent
to counteract drug-related hemorrhage.
Figure 1
Figure 1. Points of Intervention on the Clotting Cascade of New Direct thrombin 
inhibitor Ximelagatran. Warfarin interferes with the production of factors II,VII, IX 
and X
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Additional advantages of direct thrombin inhibitors
include a targeted specificity for thrombin, the ability to
inactivate clot-bound thrombin, and an absence of
plasma protein and platelet interactions, which can lead
to complications such as heparin-induced
thrombocytopenia.
The SPORTIF studies
SPORTIF II was a 12-week, randomized, parallel group,
dose-guiding study in non-valvular AF (NVAF) patients
with at least one additional risk factor for stroke [56]. The
primary endpoint was the number of thromboembolic
events and bleedings. Three groups received ximelagatran
(n = 187) at 20, 40, or 60 mg twice daily, given in a dou-
ble-blind fashion, without routine coagulation monitor-
ing. In a fourth group, warfarin (n = 67) was managed and
monitored according to normal routines, aiming for an
INR of 2.0 to 3.0. All three doses of ximelagatran com-
pared favorably with warfarin, without the need for dose
adjustment or coagulation monitoring.
The SPORTIF III and V are phase III trials designed with
the primary objective of establishing the non-inferiority of
ximelagatran relative to warfarin for the prevention of all
strokes (ischemic and hemorrhagic) and systemic embolic
events in patients with AF (persistent and paroxysmal)
who have one or more additional risk factors for stroke
[57]. To be included, patients were required to have per-
sistent or paroxysmal non-valvular AF verified by at least
two ECG recordings, one of which was made within two
weeks of randomization. Secondary endpoints were
death, acute myocardial infarction, major and minor
bleeding, and discontinuation of treatment. SPORTIF III
was conducted over 259 European sites as an open-label
study, with blinded endpoint assessment. SPORTIF V was
a double-blind study involving 409 North American sites.
In both studies, patients were randomized to either a fixed
36 mg, twice-daily dose of ximelagatran or to warfarin
(INR 2.0–3.0, monitoring interval ≤ 4 weeks) [56].
The two trials were well matched, with a mean patient age
of 70 years (69% males). Seventy-two percent of patients
had > 1 risk factor for thromboembolism.
SPORTIF III
The SPORTIF III trial (see Table 5 and Additional file: 5)
included 3,410 patients (mean follow up 17.4 months)
[58]. The INR values fell within the intended therapeutic
range for the entire duration of exposure in 66% of the
study population, and values were within the extended
range of 1.8 to 3.2 more than 80% of the time, a rate much
better than in most published reports or experienced in
clinical practice. By intention-to-treat analysis, there was
no difference in the primary endpoint (rates of stroke or
systemic embolic events) between warfarin (56: 2.3%/yr)
and ximelagatran (40: 1.6%/yr). However primary events
in on-treatment analysis were significantly lower in the
ximelagatran (29, 1.3%/yr) versus warfarin-treated
patients (52, 2.2%/yr; RRR 43%, p = 0.018). The com-
bined rate of major and minor bleeding events was found
to be significantly lower for ximelagatran than for warfa-
rin (475 vs 554 events; p = 0.007). There was no signifi-
cant difference in all-cause mortality between the
ximelagatran (78: 3.2%) and warfarin groups (79: 3.2%),
despite the lack of coagulation monitoring and fixed-dose
regimen with ximelagatran. There was a "net clinical ben-
efit" (combined rate of primary events, major bleeding,
and death with each treatment) in favor of ximelagatran
treatment (6.1%/year with warfarin and 4.6%/year with
ximelagatran, RRR 25%, p = 0.022).
There was no difference in the overall rate of adverse
events between patients randomized to warfarin (1,452,
85%) and those assigned to ximelagatran (1,472, 87% p =
0.228). The serum concentration of alanine aminotrans-
ferase rose >3 × the upper limit of normal in 14 (1%)
patients in the warfarin group and 107 (6%) in the
ximelagatran group (p < 0.0001, see table 5 and Addi-
tional file: 5). Of the 107 patients in the ximelagatran
group, 48 discontinued the study drug prematurely (42 of
48 returned to normal), and 59 continued treatment with
raised serum concentrations of alanine aminotransferase.
Fifty-five of these returned to normal, three returned to
less than twice the upper limit of normal, and one in
whom the amount of alanine aminotransferase was
greater than twice the upper limit of normal before the
study remained at this value.
SPORTIF V
The SPORTIF V trial (see Table 5 and Additional file: 5)
included 3,922 patients with NVAF. Study results have
been presented but not yet published [59]. Anticoagula-
tion with warfarin was meticulously monitored. The INR
remained within the target range 68% of the time and
within an extended INR range of 1.8–3.2 eighty-three per-
cent of the time, where no dose adjustment would be
deemed necessary. The difference in primary event rates
by intention-to-treat analysis fell within the non-inferior-
ity parameters, with an absolute difference of 0.45% per
year between groups (p = 0.13). By on-treatment analysis,
the absolute difference was +0.55% per year (95% CI -
0.06%–1.16%, p = 0.089) for ximelagatran vs warfarin.
The rates of intracerebral hemorrhage and major bleeding
were low and were not significantly different between
groups, with a trend for major bleeding that favored
ximelagatran. When all bleeding was considered, there
was a statistically significantly lower rate of major and
minor bleeding with ximelagatran compared with warfa-
rin. Elevations of serum transaminase enzymes in theCurrent Controlled Trials in Cardiovascular Medicine 2004, 5 http://cvm.controlled-trials.com/content/5/1/3
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ximelagatran group reached beyond three times the upper
limit of normal in 6% of ximelagatran patients, compared
with 0.8% in the warfarin group (table 5 and Additional
file: 5).
Summary of SPORTIF III and V
SPORTIF III and V are complementary studies that
together represent the largest combined randomized trial
of anticoagulation in AF to date. The data confirm the
non-inferiority of ximelagatran as compared to warfarin
for the prevention of embolic events in AF. In the com-
bined studies, a total of 91 patients with events were seen
for ximelagatran compared with 93 for warfarin (1.6 per-
cent/yr vs. 1.6 per percent/yr), supporting the efficacy of
ximelagatran in the prevention of strokes and throm-
boembolic events in patients with atrial fibrillation.
Ximelagatran is also associated with less combined major
and minor bleeding than warfarin.
However, optimism is tempered by the need for monitor-
ing of liver function, probably monthly, for at least the
first six months of treatment [59]. This rise in serum
transaminase typically occurred within two and six
months after initiation of treatment and then normalized,
whether or not treatment was continued.
Will ximelagatran replace warfarin?
Recent data demonstrating the efficacy of ximelagatran for
the treatment and prevention of venous thromboembo-
lism as well as for administration after myocardial infarc-
tion should give the drug a wide clinical platform [60-66].
However, improved convenience is likely to come at a sig-
nificant financial cost. Added to this limitation is encour-
aging recent mortality data about warfarin [67], and the
increasing trend toward the use of anticoagulation clinics
and home patient monitoring [68,69]. This will clearly
reduce both the cost and inconvenience of warfain use,
while furthering improved anticoagulation control.
There is no doubt that ximelagatran offers an exciting
alternative to warfarin. Nonetheless, we do feel that it is
still too early to say whether or not it will represent a via-
ble future replacement. We await longer-term data, which
are likely to become available after the launch of this
product onto the market within the next two years.
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